Ager Rage Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
AGER (Advanced Glycosylation End-Product Specific Receptor), commonly known as RAGE (Receptor for Advanced Glycation End-products), is a pattern recognition receptor that binds diverse ligands and plays a central role in chronic inflammation and neurodegeneration.
This page provides comprehensive information about the protein/gene, its function in the nervous system, and its role in neurodegenerative diseases.
RAGE is a 404 amino acid type I transmembrane protein in the immunoglobulin superfamily:
- Extracellular domain (1-330): One V-type Ig domain (NCC) + two C-type Ig domains (CC)
- Transmembrane domain (331-361): Single pass helix
- Cytoplasmic domain (362-404): Essential for signaling, TRADD-binding site
- Molecular weight: ~55 kDa (glycosylated)
- Full-length RAGE (mRAGE)
- Soluble RAGE (sRAGE): Decoy receptor, protective
- N-truncated RAGE (N-RAGE)
RAGE is expressed in neurons, glia, and endothelial cells:
- Pattern Recognition: Binds AGEs, HMGB1, S100 proteins, nucleic acids, amyloid fibrils
- Pro-inflammatory Signaling: Activates NF-κB, MAPK pathways via RAGE-DIAPH1-TRADD
- Cell Adhesion: Mediates leukocyte recruitment
- Repair Response: Transient activation promotes tissue repair
- Low in normal brain
- Upregulated in response to injury, inflammation
RAGE is a central player in AD pathogenesis:
- Aβ Binding: RAGE binds Aβ, mediating neuronal toxicity and microglial activation
- Transport: RAGE transports Aβ across the BBB
- Inflammation: Chronic NF-κB activation drives neuroinflammation
- Therapeutic Target: RAGE inhibitors in clinical trials
- Binds α-synuclein aggregates
- Promotes dopaminergic neuron death
- Associated with oxidative stress
- Stroke: Mediates post-ischemic inflammation
- ALS: Upregulated in motor neurons
- Diabetes: Links metabolic dysfunction to neurodegeneration
| Strategy |
Status |
Notes |
| RAGE inhibitors |
Clinical trials |
Azeliragon (failed), others in progress |
| sRAGE/Decoy receptors |
Research |
Recombinant sRAGE |
| Anti-RAGE antibodies |
Preclinical |
Block ligand binding |
| HMGB1 antagonists |
Research |
Prevent RAGE activation |
- Yan et al. (2009) "RAGE and Alzheimer's disease" Nat Rev Neurol[1]
- Deane et al. (2012) "RAGE mediates amyloid-β peptide transport across the blood-brain barrier" J Clin Invest[2]
RAGE activates multiple intracellular signaling cascades that contribute to neuroinflammation and neurodegeneration:
- NF-κB pathway: Leads to upregulation of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α
- MAPK pathways: Including p38, JNK, and ERK signaling
- RAGE-DIAPH1 axis: Promotes cytoskeletal reorganization and migration
- TLR4 co-activation: Synergistic inflammation with toll-like receptor 4
Multiple RAGE inhibitors have been developed for neurodegenerative diseases:
| Drug |
Mechanism |
Status |
| Azeliragon |
RAGE antagonist |
Phase 3 for AD |
| PF-04494700 |
RAGE inhibitor |
Phase 2 for AD |
| TTP-488 |
RAGE antagonist |
Phase 2 for AD |
Key research areas include:
- Developing brain-penetrant RAGE inhibitors
- Understanding RAGE isoforms and their specific roles
- Biomarker development using soluble RAGE (sRAGE)
- Combination therapies targeting RAGE and other pathways[^1]
RAGE (Receptor for Advanced Glycation Endproducts) is a pattern recognition receptor that binds to multiple damage-associated molecular patterns (DAMPs) including advanced glycation endproducts (AGEs), S100 proteins, HMGB1, amyloid-beta fibrils, and nucleic acids. Upon ligand binding, RAGE activates multiple pro-inflammatory signaling cascades including NF-κB, MAPK, and AP-1 pathways.
RAGE exists in multiple isoforms:
- Full-length RAGE (membrane-bound)
- Soluble RAGE (sRAGE) - endogenous decoy
- N-truncated RAGE
The receptor is expressed in neurons, microglia, astrocytes, and vascular endothelial cells, making it a key mediator of neuroinflammation in neurodegenerative diseases.
In Alzheimer's disease, RAGE contributes to:
- Aβ-induced neuroinflammation through microglial activation
- Neuronal apoptosis and synaptic dysfunction
- Blood-brain barrier disruption
- Oxidative stress amplification
- Tau pathology progression through NF-κB-mediated kinases
RAGE expression is upregulated in AD brain regions with high amyloid plaque burden, particularly in the hippocampus and cerebral cortex.
In Parkinson's disease, RAGE mediates:
- Alpha-synuclein-induced neuroinflammation
- Microglial activation and dopaminergic neuron death
- Mitochondrial dysfunction through ROS generation
- Blood-brain barrier permeability changes
RAGE represents a promising therapeutic target:
- RAGE inhibitors (e.g., FPS-ZM1, small-molecule blockers)
- sRAGE as a decoy receptor
- Anti-RAGE antibodies
- Natural compounds (e.g., curcumin, resveratrol) with RAGE-modulating activity
- Lifestyle interventions that reduce AGE formation
Soluble RAGE (sRAGE) levels in cerebrospinal fluid and blood serve as:
- Biomarker for disease progression in AD and PD
- Indicator of neuroinflammatory activity
- Potential predictor of treatment response
The study of Ager Rage Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Han SH, et al. (2019). 'RAGE and Alzheimer's disease.' Nature Reviews Neurology. PMID:31118454
- Kierdorf K, et al. (2013). 'RAGE in immune responses.' Immunity. PMID:23340052
- Deane RJ. (2012). 'RAGE and Alzheimer's disease.' Biochemical Society Transactions. PMID:22817730
- Srikanth V, et al. (2011). 'RAGE and diabetic complications.' Diabetes Care. PMID:21464461
RAGE (Receptor for Advanced Glycation Endproducts) is a pattern recognition receptor that binds to multiple damage-associated molecular patterns (DAMPs) including advanced glycation endproducts (AGEs), S100 proteins, HMGB1, amyloid-beta fibrils, and nucleic acids. Upon ligand binding, RAGE activates multiple pro-inflammatory signaling cascades including NF-κB, MAPK, and AP-1 pathways.
RAGE exists in multiple isoforms:
- Full-length RAGE (membrane-bound)
- Soluble RAGE (sRAGE) - endogenous decoy
- N-truncated RAGE
The receptor is expressed in neurons, microglia, astrocytes, and vascular endothelial cells, making it a key mediator of neuroinflammation in neurodegenerative diseases.
In Alzheimer's disease, RAGE contributes to:
- Aβ-induced neuroinflammation through microglial activation
- Neuronal apoptosis and synaptic dysfunction
- Blood-brain barrier disruption
- Oxidative stress amplification
- Tau pathology progression through NF-κB-mediated kinases
RAGE expression is upregulated in AD brain regions with high amyloid plaque burden, particularly in the hippocampus and cerebral cortex.
In Parkinson's disease, RAGE mediates:
- Alpha-synuclein-induced neuroinflammation
- Microglial activation and dopaminergic neuron death
- Mitochondrial dysfunction through ROS generation
- Blood-brain barrier permeability changes
RAGE represents a promising therapeutic target:
- RAGE inhibitors (e.g., FPS-ZM1, small-molecule blockers)
- sRAGE as a decoy receptor
- Anti-RAGE antibodies
- Natural compounds (e.g., curcumin, resveratrol) with RAGE-modulating activity
- Lifestyle interventions that reduce AGE formation
Soluble RAGE (sRAGE) levels in cerebrospinal fluid and blood serve as:
- Biomarker for disease progression in AD and PD
- Indicator of neuroinflammatory activity
- Potential predictor of treatment response
[1] RAGE and Alzheimer disease. PMID:20054047